Dr. Hearn Jay Cho, MD

Dr. Cho practices at The Mount Sinai Hospital in New York, New York, part of Mount Sinai Health System.

Dr. Cho's NPI, 1225060080, was assigned on July 6, 2006. Dr. Cho graduated from Weill Cornell Medicine in 1996. Dr. Cho holds New York license 217180.

Dr. Cho's primary practice is The Mount Sinai Hospital, at One Gustave L Levy Place, New York, NY 10029 in New York County. The practice phone is (212) 241-7981. Dr. Cho also practices at The Mount Sinai Hospital, 1 Gustave L Levy Pl, New York, NY 10029.

Dr. Cho's primary practice is The Mount Sinai Hospital in New York, New York, part of Mount Sinai Health System. The medical group on file is NYU Langone Orthopedic Surgery Associates. Dmand AI also links Dr. Cho to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Cho practices, 3 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Cho's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Cho is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Cho's licenses on file in 5 states: New York, California, Florida, New Jersey and Connecticut.

Dmand AI lists multiple myeloma among the conditions Dr. Cho treats.

CMS data shows 186 Medicare services from Dr. Cho across 2 procedure codes in 2024, all of them office visits, for 59 Medicare patients. Medicare paid $17,094 for them.

CMS counts 59 Medicare patients who saw Dr. Cho in 2024. The largest group is 65 to 74, with 24 patients. 69% of them have high cholesterol, and 68% have high blood pressure. Their average risk score is 3.40, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Cho's median patient age at 70, with 49% women.

In 2024, Dr. Cho wrote 137 Medicare Part D claims for 28 patients. 93% of them were for generic drugs. CMS names the drug for 90 of them, across 3 drugs with 11 or more claims each, at $750 in total drug cost. In 2023, CMS named 88 claims across 3 drugs.

Dr. Cho accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Cho as offering telehealth.

Dmand AI links 78 papers to Dr. Cho, published from 2005 to 2025. 2020 was the busiest year, with 13. The most frequent topics are Multiple Myeloma, Antineoplastic Combined Chemotherapy Protocols and Antigens, Neoplasm. Dr. Cho has published most often in Clin Lymphoma Myeloma Leuk. Dr. Cho's most frequent co-authors are Sundar Jagannath, MD, Samir Sunil Parekh, MD and Ajai Chari, MD.

Dmand AI links Dr. Cho to 4 clinical trials, 3 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Multiple Myeloma, Blood Protein Disorders and Immunoglobulin Light-chain Amyloidosis.

CMS Open Payments shows 85 general payments to Dr. Cho from 16 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 48% of the total. Celgene Corporation paid the most, $33,672.

Dmand AI lists 1 award for Dr. Cho, most recently CMS Stage 1 EHR in 2013.

Dr. Cho graduated from Weill Cornell Medicine in 1996. Dr. Cho is a member of ASCO.

Dr. Cho is in network with 17 carriers, including Aetna, Elevance and United Healthcare. Medicare plans come from the most carriers, 11. Check the plan with the practice before a visit.